Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Familial hypocalciuric hypercalcemia Indication Strategy Report 2026: CaSR, Trials and Deals
23 July 2026
2026 Familial hypocalciuric hypercalcemia strategy: epidemiology, CaSR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Familial tumoral calcinosis Indication Strategy Report 2026: FGF23, Trials and Deals
23 July 2026
2026 Familial tumoral calcinosis strategy: epidemiology, FGF23 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pseudohypoparathyroidism Indication Strategy Report 2026: PTH1R, Trials and Deals
23 July 2026
2026 Pseudohypoparathyroidism strategy: epidemiology, PTH1R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Progressive osseous heteroplasia Indication Strategy Report 2026: GNAS, Trials and Deals
23 July 2026
2026 Progressive osseous heteroplasia strategy: epidemiology, GNAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Fibrodysplasia ossificans progressiva Indication Strategy Report 2026: ACVR1, Trials and Deals
23 July 2026
2026 Fibrodysplasia ossificans progressiva strategy: epidemiology, ACVR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Osteogenesis imperfecta Indication Strategy Report 2026: Sclerostin, Trials and Deals
23 July 2026
2026 Osteogenesis imperfecta strategy: epidemiology, Sclerostin biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hypophosphatasia Indication Strategy Report 2026: ALPL, Trials and Deals
23 July 2026
2026 Hypophosphatasia strategy: epidemiology, ALPL biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
X-linked hypophosphatemia Indication Strategy Report 2026: FGF23, Trials and Deals
23 July 2026
2026 X-linked hypophosphatemia strategy: epidemiology, FGF23 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tumor-induced osteomalacia Indication Strategy Report 2026: FGF23, Trials and Deals
23 July 2026
2026 Tumor-induced osteomalacia strategy: epidemiology, FGF23 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Guanidinoacetate methyltransferase deficiency Indication Strategy Report 2026: GAMT, Trials and Deals
23 July 2026
2026 Guanidinoacetate methyltransferase deficiency strategy: epidemiology, GAMT biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Creatine transporter deficiency Indication Strategy Report 2026: SLC6A8, Trials and Deals
23 July 2026
2026 Creatine transporter deficiency strategy: epidemiology, SLC6A8 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tyrosine hydroxylase deficiency Indication Strategy Report 2026: TH, Trials and Deals
23 July 2026
2026 Tyrosine hydroxylase deficiency strategy: epidemiology, TH biology, clinical competition, recent deals, unmet need and market attractiveness.